Tetraphase Pharmaceuticals Inc., of Watertown, Mass., said it entered an exclusive licensing agreement with Everest Medicines Ltd., a C-Bridge Capital-backed company based in China, to develop and commercialize eravacycline in mainland China, Taiwan, Hong Kong, Macau, South Korea and Singapore.